HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/ 3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high- grade vulvar (VIN 2/ 3) and vaginal (VaIN 2/ 3) intraepithelial neoplasia.
HPV 16 ja HPV 18 põhjustavad hinnanguliselt umbes 70% emakakaelavähi; 80% in situ adenokartsinoomi (AIS); 45... 70% emakakaela kõrge astme intraepiteliaalse neoplaasia (CIN II/ III); 25% emakakaela madala astme intraepiteliaalse neoplaasia (CIN I) ning ligikaudu 70% HPV- ga seotud häbeme (VIN II/ III) ja tupe (VaIN II/ III) kõrge astme intraepiteliaalse neoplaasia juhtudest.